Table 1.
Clinical and histopathological characteristics of the patient population
| Pat | Sexa | Ageb | Locationc | Initial diagnolis |
No. rec.f | Treatment course prior to B/I therapyg |
Before B/I therapy |
PFS/OS analysis |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TU typed | KPSe | Surgeryh | Radiationi | Chemotherapyj | TU typed | KPSe | PFSk | OSl | |||||
| 1 | M | 60 | R, F-P | AA III | 100 | 1 | (0) SB | (0) 60 Gy | (0) TMZ | sGBM IV (MRI) | 60 | 4.4 | 16.4 |
| 2 | F | 37 | R, T | GBM IV | 90 | 2 | (0) MTR (1) MTR, (2) MTR |
(0) 60 Gy | (0) TMZ (1) TMZ |
GBM IV | 70 | 4.93 | 81.9 |
| 3 | M | 66 | R, T | GBM IV | 90 | 3 | (0) MTR (1) MTR, (3) MTR |
(0) 60 Gy | (0) TMZ (1) SUT, (2) TMZ |
GBM IV | 60 | 2.83 | 45.7 |
| 4 | M | 55 | R, F | GBM IV | 90 | 2 | (0) PR (1) MTR |
(0) 60 Gy (1) Booster, (2) WBR |
(0) TMZ (1) TMZ (2) lip.Cyt-Ara |
GBM IV | 70 | 1.47 | 31.2 |
| 5 | F | 69 | R, T | GS IV | 90 | 2 | (0) MTR | (0) 60 Gy | (0) TMZ (1) SUT |
GS IV | 50 | 4.47 | 23.3 |
| 6 | M | 37 | R, F-T | A II | 100 | 2 | (0) MTR (1) MTR |
(0) 60 Gy | - (1) Caelyx |
sGBM IV (H) | 60 | 7.6 | 113.6 |
| 7 | M | 33 | L-R, F | OA II | 100 | 5 | (0) PR (1) MTR, (4) MTR |
(0) 60 Gy (1) 60 Gy |
- (3) PCV, (4) TMZ |
sGBM IV (H) | 70 | 3.07 | 169.5 |
| 8 | F | 62 | L, P | AA III | 60 | 1 | (0) PR | (0) 60 Gy | (0) TMZ | sGBM IV (MRI) | 50 | No progress | Alive |
| 9 | M | 60 | L, P | GBM IV | 100 | 2 | (0) MTR | (0) 60 Gy | (0) TMZ (1) TMZ |
GBM IV | 70 | 5.53 | Alive |
| 10 | F | 46 | L, F | ODG III–IV | 90 | 3 | (0) PR (1) MTR, (2) MTR |
- (1, 2) 60 Gy |
(0) PCV (1) TMZ |
sGBM IV (H) | 80 | 10.2 | 50.4 |
| 11 | M | 27 | R, F | GBM IV | 100 | 2 | (0) PR | (0) 60 Gy | (0) TMZ (1) TMZ |
GBM IV | 100 | 4.77 | 22.6 |
| 12 | M | 44 | R, F | AA III | 90 | 3 | (0) PR | (0) 60 Gy | (0) PCV (1) TMZ, (2) TMZ |
sGBM IV (MRI) | 90 | No progress | Alive |
| 13 | F | 82 | R, T-F-P | A II | 90 | 2 | (0) PR (1) MTR |
(0) 60 Gy | (0) TMZ (1) TMZ |
sGBM IV (MRI) | 60 | 5.47 | 72.5 |
| 14 | M | 63 | L, P | GBM IV | 80 | 2 | (0) PR | (0) 60 Gy | (0) TMZ (1) SUT |
GBM IV | 80 | 1.9 | 18.2 |
Sex: M male, F female
Age at initial diagnosis
Tumor location: L left hemisphere, R right hemisphere, F frontal, P parietal, O occipital, T temporal, BS brainstem
Tumor type (histology at initial diagnosis or H, histology/MRI, MRI diagnosis before B/I therapy) + WHO grading—GBM glioblastoma multiforme IV, GS gliosarcoma IV, AA anaplastic astrocytoma III, A fibrillary astrocytoma II, ODG oligodendroglioma II or III, OA oligoastrocytoma II or III, sGBM IV secondary GBM (H histology, MRI MRI diagnosis)
Karnofsky performace status (KPS) at initial diagnosis and before B/I therapy
Number of recurrences during treatment course
Treatment course: (0) primary tumor, (1) 1st recurrence, (n) no recurrence until death/evaluation
Surgery: MTR macroscopic total resection, PR partial resection, SB stereotactic biopsy
Radiation: extended field radiation with cumulative dose in Gray (Gy); WBR whole brain radiation with cumulative dose in Gray (Gy)
TMZ temozolomide, PCV procarbazine, lomustine, vincristine, SUT sunitinib (according to SURGE 01-07 study protocol); caelyx® anthracyclin, lip. Cyt-Ara liposomal cytosin arabinoside (Depocyte ®)
Progression-free survival, time in months from commencement of B/I treatment to progression in T1 and T2 MRI sequences
Overall survival (OS), time in months from first tumor occurrence to death